2-甲氧基-6-甲基苯甲腈 | 53005-44-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-甲氧基-6-甲基苯甲腈
• 中文别名: 2-甲基-6-甲氧基苯腈；2-甲氧基-6-甲基苯腈；2-甲基-6-甲氧基苯甲腈
• 英文名称: 2-methoxy-6-methyl-benzonitrile
• 英文别名: 2-methoxy-6-methylbenzonitrile；2-Methoxy-6-methyl-benzonitril；6-Methoxy-o-tolunitril
• CAS: 53005-44-0
• 化学式: C₉H₉NO
• mdl: MFCD10699539
• 分子量: 147.177
• InChiKey: ZZZIUEZLZGDVBG-UHFFFAOYSA-N

物化性质

• 沸点：
  70-74℃ (0.4 Torr)
• 密度：
  1.06±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  33
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2926909090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温且干燥环境下使用。

反应信息

• 作为反应物：
  描述：

  2-甲氧基-6-甲基苯甲腈 在 N-溴代丁二酰亚胺(NBS) 、 三氟乙酸 作用下， 反应 16.0h， 生成 3-溴-6-甲氧基-2-甲基苯甲腈
  参考文献：
  名称：

  [EN] INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL
  [FR] INHIBITEURS DU CANAL À POTASSIUM DE LA MEDULLA EXTERNE DU REIN

  摘要：

  本发明提供了式（I）的化合物及其药用可接受的盐，这些化合物是ROMK（Kir1.1）通道的抑制剂。这些化合物作为利尿剂和钠利尿剂，并且是治疗和预防包括高血压在内的心血管疾病以及由过多盐分和水潴留导致的疾病的有价值的药用活性化合物。

  公开号：

  WO2013090271A1
• 作为产物：
  描述：

  2-甲氧基-6-甲基苯甲酰胺 在 吡啶 、 三氟乙酸酐 作用下， 以 二氯甲烷 为溶剂， 以91%的产率得到2-甲氧基-6-甲基苯甲腈
  参考文献：
  名称：

  Heteroatom-directed metalation. Lithiation of N-propenylbenzamides and N-propenyl-o-toluamides. Novel routes to ortho-substituted primary benzamide derivatives and N-unsubstituted isoquinolin-1(2H)-ones

  摘要：

  Reaction of N-propenylbenzamides 4 and 9, obtained by LDA-induced isomerization of the corresponding N-allylbenzamides 1, 8, and 14, with 2 equiv of sec-butyllithium or tert-butyllithium at low temperature regiospecifically generates the highly reactive N,ortho-dilithiated species (e.g., 5 and 17). These dilithio species react avidly with a wide spectrum of electrophilic reagents, including alkyl halides, giving adducts which on hydrolysis with warm 50% aqueous acetic acid are converted into ortho-substituted primary benzamides in excellent yields. Ortho-lithiation of N-propenylbenzamides is thus formally equivalent to ortho-lithiation of primary benzamides themselves. The utility of this important, previously unknown, synthetic operation is enhanced by the well-known facility with which the primary amide moiety can be transformed into other useful functional groups, as exemplified by the synthesis of 2-methoxy-6-methylbenzoic acid (12) and 2-methoxy-6-methylbenzonitrile (13) from N-propenyl-2-methoxybenzamide (9), N-Propenyl-o-toluamide (7) undergoes regiospecific dilithiation on nitrogen and on the methyl group under conditions analogous to those used for the N-propenylbenzamides. These dilithio species react with DMF or "Weinreb type" amides to give condensation products which cyclize to N-propenylisoquinolin-1(2H)-ones under midly acidic conditions. Removal of the N-propenyl moiety under more strongly acidic conditions provides N-unsubstituted isoquinolin-1(2H)-ones with high overall efficiency. This process is exemplified by the synthesis of isoquinolin-1(2H)-one (23) and its 3-n-butyl congener 26 from N-propenyl-2-methylbenzamide (7).

  DOI：

  10.1021/jo00035a030

文献信息

• N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
  申请人：Rodgers James D.

  公开号：US20100298334A1

  公开（公告）日：2010-11-25

  The present invention relates to N-(hetero)aryl-pyrrolidine derivatives of Formula I: which are JAK inhibitors, such as selective JAK1 inhibitors, useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.

  本发明涉及式I的N-(杂)芳基吡咯烷衍生物： 这些是JAK抑制剂，如选择性JAK1抑制剂，在治疗JAK相关疾病方面具有用处，例如炎症和自身免疫性疾病，以及癌症。
• [EN] 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER<br/>[FR] DÉRIVÉS DE 2-CYANOISOINDOLINE POUR LE TRAITEMENT DU CANCER
  申请人：MISSION THERAPEUTICS LTD

  公开号：WO2017158388A1

  公开（公告）日：2017-09-21

  The invention relates to novel compounds of formula I which are inhibitors of deubiquitylating enzymes (DUBs) and/or desumoylating enzymes. In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 7 or ubiquitin specific peptidase 7 (USP7). The invention further relates to methods for the preparation of these compounds and to their use in the treatment of cancer.

  这项发明涉及公式I的新化合物，这些化合物是去泛素化酶（DUBs）和/或去泛素化酶的抑制剂。具体来说，该发明涉及抑制泛素C端水解酶7或泛素特异性肽酶7（USP7）。该发明还涉及这些化合物的制备方法以及它们在癌症治疗中的应用。
• NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES
  申请人：NAGARATHNAM Dhanapalan

  公开号：US20120289496A1

  公开（公告）日：2012-11-15

  The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.

  本发明提供了PI3K蛋白激酶调节剂，其制备方法，含有它们的药物组合物，以及使用它们进行治疗、预防和/或改善激酶介导的疾病或紊乱的方法。
• Electrochemical C−H Cyanation of Electron-Rich (Hetero)Arenes
  作者：Davit Hayrapetyan、Raja K. Rit、Markus Kratz、Kristina Tschulik、Lukas J. Gooßen

  DOI：10.1002/chem.201802247

  日期：2018.8.6

  straightforward method for the electrochemical C−H cyanation of arenes and heteroarenes that proceeds at room temperature in MeOH, with NaCN as the reagent in a simple, open, undivided electrochemical cell is reported. The platinum electrodes are passivated by adsorbed cyanide, which allows conversion of an exceptionally broad range of electron‐rich substrates all the way down to dialkyl arenes. The cyanide electrolyte

  据报道，芳烃和杂芳烃的CH-H氰化的直接方法是在室温下于MeOH中进行，NaCN作为试剂在简单，开放，不分隔的电化学池中进行。铂电极被吸附的氰化物钝化，从而可以将范围广泛的富电子底物一直转化为二烷基芳烃。氰化物电解质可以补充HCN，为无盐工业CH氰化打开了机会。
• [EN] INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL<br/>[FR] INHIBITEURS DU CANAL POTASSIQUE MÉDULLAIRE EXTÉRIEUR RÉNAL
  申请人：MERCK SHARP & DOHME

  公开号：WO2013062892A1

  公开（公告）日：2013-05-02

  The present invention provides compounds of Formula (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir 1.1) channel. The compounds act as diuretics and natriuretics and are valuable pharmaceutically active compounds for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension and conditions resulting from excessive salt and water retention.

  本发明提供了式（I）的化合物及其药学上可接受的盐，这些化合物是ROMK（Kir 1.1）通道的抑制剂。这些化合物作为利尿剂和钠利尿剂，并且是治疗和预防包括高血压和由过多盐和水潴留引起的疾病等医学状况的有价值的药用活性化合物。